143 related articles for article (PubMed ID: 37572539)
41. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
42. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
Freeman DB; Hopkins TD; Mikochik PJ; Vacca JP; Gao H; Naylor-Olsen A; Rudra S; Li H; Pop MS; Villagomez RA; Lee C; Li H; Zhou M; Saffran DC; Rioux N; Hood TR; Day MAL; McKeown MR; Lin CY; Bischofberger N; Trotter BW
J Med Chem; 2023 Dec; 66(23):15629-15647. PubMed ID: 37967851
[TBL] [Abstract][Full Text] [Related]
43. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
Xu Z; Zhang B; Liu Z; Gou S
Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
[TBL] [Abstract][Full Text] [Related]
45. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
[TBL] [Abstract][Full Text] [Related]
46. Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9.
Jia Q; Hu Z; Song N; Mao W
Cardiovasc Drugs Ther; 2023 Jun; 37(3):449-460. PubMed ID: 35088192
[TBL] [Abstract][Full Text] [Related]
47. The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.
Zhou F; Tang L; Le S; Ge M; Cicic D; Xie F; Ren J; Lan J; Lu Q
Oncotarget; 2023 Dec; 14():997-1008. PubMed ID: 38117531
[TBL] [Abstract][Full Text] [Related]
48. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
49. BIRC6 mediates imatinib resistance independently of Mcl-1.
Okumu DO; East MP; Levine M; Herring LE; Zhang R; Gilbert TSK; Litchfield DW; Zhang Y; Graves LM
PLoS One; 2017; 12(5):e0177871. PubMed ID: 28520795
[TBL] [Abstract][Full Text] [Related]
50. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Fiskus W; Manshouri T; Birdwell C; Mill CP; Masarova L; Bose P; Kadia TM; Daver N; DiNardo CD; Borthakur G; Khoury JD; Verstovsek S; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):23. PubMed ID: 35102145
[No Abstract] [Full Text] [Related]
52. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
53. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
54. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.
Garcia-Cuellar MP; Füller E; Mäthner E; Breitinger C; Hetzner K; Zeitlmann L; Borkhardt A; Slany RK
Leukemia; 2014 Jul; 28(7):1427-35. PubMed ID: 24445865
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
57. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Eriksson A; Kalushkova A; Jarvius M; Hilhorst R; Rickardson L; Kultima HG; de Wijn R; Hovestad L; Fryknäs M; Öberg F; Larsson R; Parrow V; Höglund M
Biochem Pharmacol; 2014 Jan; 87(2):284-91. PubMed ID: 24200998
[TBL] [Abstract][Full Text] [Related]
58. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
[TBL] [Abstract][Full Text] [Related]
59. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
[TBL] [Abstract][Full Text] [Related]
60. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Cidado J; Boiko S; Proia T; Ferguson D; Criscione SW; San Martin M; Pop-Damkov P; Su N; Roamio Franklin VN; Sekhar Reddy Chilamakuri C; D'Santos CS; Shao W; Saeh JC; Koch R; Weinstock DM; Zinda M; Fawell SE; Drew L
Clin Cancer Res; 2020 Feb; 26(4):922-934. PubMed ID: 31699827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
